Redeye endorses today’s news that the first healthy volunteers have been dosed in the second part of the phase Ia trial with HER-096. In this section of the trial, “12-16 elderly healthy volunteers, both males and females, will be administered with a single dose of HER-096 to evaluate the blood-brain-barrier penetration of HER-096”. The company expects to present top-line data in Q4 this year. We are encouraged to learn that the trial is progressing well and will return with a more thorough comment in relation the report later this week.
LÄS MER
